Mentara Therapeutics raised initial funding to advance its asset portfolio and launch a Phase 2 clinical study. Backed by SPRIM Global Investments and former shareholders of EuMentis Therapeutics.
Round Type
Venture
Investors
Description
Mentara Therapeutics, based in Melbourne, Australia, has successfully raised capital in its initial strategic financing round. The funds will be used to further develop its neurological therapies and scale up manufacturing operations. The company aims to conduct a Phase 2 clinical study for its lead drug candidate in patients with Parkinson's disease. Mentara is focused on treating neurodegenerative and neuropsychiatric diseases.
Quick answer
Mentara Therapeutics raised an undisclosed amount in a funding round, dated October 12, 2026. Investors: former shareholders of EuMentis Therapeutics and Sprim Global Investments. Mentara Therapeutics is based in Melbourne, Victoria, Australia.
- How much did Mentara Therapeutics raise?
- Mentara Therapeutics raised an undisclosed amount in a funding round on October 12, 2026.
- Who invested in Mentara Therapeutics?
- former shareholders of EuMentis Therapeutics and Sprim Global Investments are named as investors in this round.
- What does Mentara Therapeutics do?
- Mentara Therapeutics is a Melbourne-based developer specializing in treatments for neurodegenerative and neuropsychiatric diseases.
- Where is Mentara Therapeutics based and how big is it?
- Mentara Therapeutics is based in Melbourne, Victoria, Australia.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Mentara Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- VectorY raised $83M on November 11, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
Who to call at Mentara Therapeutics, and when
A new round usually means Mentara Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Mentara Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Mentara Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Mentara Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Mentara Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Mentara Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.